承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而產生或因依賴該等內容而引致的任何 損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 康 灃 生 物 科 技（ 上 海 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6922） 2025年第一次臨時股東大會通告 茲通告康灃生物科技（上海）股份有限公司（「本公司」）謹訂於2025年10月31日 （星期五）上午十時正假座中國上海市浦東新區康新公路3399弄25號樓3樓舉行2025年 第一次臨時股東大會（「臨時股東大會」），以考慮及酌情通過下列決議案。除另有所指 外，本通告所用詞彙與本公司日期為2025年10月14日的通函（「通函」）所界定者具有相 同涵義，其中臨時股東大會召開通告構成通函的一部分。 特別決議案 康灃生物科技（上海）股份有限公司 董事長 李克儉先生 香港 2025年10月14日 於本通告日期，董事會包括執行董事李克儉先生、朱軍先生及劉偉先生，非執行 董事呂 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證券交 易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下所有康灃生物科技（上海）股份有限公司股份，應立即將本通函連同隨附的 代表委任表格送交買主、承讓人、經手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買主 或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 康 灃 生 物 科 技（ 上 海 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6922） (1)建議修訂公司章程及廢除監事會； (2)建議廢除議事規則； 及 (3) 2025年第一次臨時股東大會通告 召開2025年第一次臨時股東大會（「臨時股東大會」）之通告載於本通函第EGM-1頁至EGM-3頁，大 會將於2025年10月31日（星期五）上午十時正假 ...

（股份代號：6922） 公告 建議修訂公司章程及取消監事會；及 建議廢除議事規則 本公告乃由康灃生物科技（上海）股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第13.51(1)條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 康灃生物科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 建議修訂公司章程及取消監事會 為全面貫徹落實法律法規及監管要求，進一步提升公司治理水平，根據《中華人 民共和國公司法》（「《公司法》」）及其他法律、法規及規範性文件的規定，結合本 公司實際情況並遵循審慎、適宜及必要原則，本公司建議對本公司的公司章程 （「公司章程」）進行修訂，以取消本公司監事會（「監事會」），而由本公司董事（「董 事」）會（「董事會」）轄下審核委員會行使《公司法》規定的監事會的職權，且本公 司監事會議事規則及其他相關規則均相應廢除。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: 康灃生物科技（上海）股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143, ...

Financial Performance - Revenue increased from RMB 19.5 million for the six months ended June 30, 2024, to RMB 51.1 million for the six months ended June 30, 2025, representing a growth of 162.4%[6] - Gross profit rose to RMB 34.3 million in the first half of 2025, compared to RMB 15.3 million in the same period of 2024[6] - The loss for the period decreased significantly from RMB 56.0 million in the first half of 2024 to RMB 27.2 million in the first half of 2025, a reduction of 51.4%[7] - Revenue for the six months ended June 30, 2025, was RMB 51,106,000, a significant increase of 162% compared to RMB 19,475,000 for the same period in 2024[84] - Gross profit for the same period was RMB 34,312,000, up from RMB 15,281,000, reflecting a gross margin improvement[84] - The net loss for the six months ended June 30, 2025, was RMB 27,221,000, a 51% improvement compared to a net loss of RMB 55,953,000 in the prior year[85] - The group reported a pre-tax loss of RMB 23,817,000 for the six months ended June 30, 2025, compared to a loss of RMB 52,171,000 for the same period in 2024, representing a 54.4% improvement[109] Research and Development - Research and development expenses decreased from RMB 37.2 million in the first half of 2024 to RMB 17.9 million in the first half of 2025[6] - The company has a product development team consisting of 33 internal R&D staff and 16 clinical operation staff as of June 30, 2025[29] - The group’s research and development expenses for the six months ended June 30, 2025, were RMB 17,907,000, a decrease of 52% from RMB 37,222,000 in the same period of 2024[103] - The company plans to invest 15% of its revenue into research and development for new product innovations and technologies[126] Product Development and Approvals - The malignant stenosis cryoablation system received approval from the National Medical Products Administration in March 2025 and was commercialized in May 2025[7] - The asthma cryoablation system was granted breakthrough medical device designation by the U.S. Food and Drug Administration in July 2025[7] - The registration change for the disposable cryo probe of the cryoadhesion treatment system was approved by the National Medical Products Administration in August 2025[7] - The company focuses on minimally invasive cryoablation technology and has established a comprehensive product portfolio targeting cardiovascular and respiratory diseases[8] - The company has developed a comprehensive product portfolio, including 14 cryoablation products targeting vascular intervention and NOTES, with 11 products commercialized as of June 30, 2025[9] - The cardiac cryoablation system is expected to receive regulatory approval by December 2023, with commercialization planned for January 2024 in China[10] - The Cryofocus cryoablation system for resistant hypertension is anticipated to gain regulatory approval in the second half of 2027[11] - The pulmonary hypertension cryoablation system is currently in preclinical research, with expected regulatory approval by the second half of 2029[12] - The COPD cryo-spray treatment system is entering confirmatory clinical trials, with registration documents expected to be submitted by the second half of 2025 and approval anticipated by the second half of 2026[13] - The asthma cryoablation system is also in confirmatory clinical trials, with expected registration submission in the second half of 2025 and approval by the second half of 2026[14] - The malignant stricture cryoablation system is expected to be commercialized by March 2025[9] - The bladder cryoablation system has already been commercialized as of June 2022[9] Financial Position and Liquidity - Cash and cash equivalents increased from RMB 45.5 million to RMB 63.7 million, an increase of RMB 18.2 million or 40.1%[46] - Total bank borrowings amounted to RMB 25.7 million as of June 30, 2025, down from RMB 30.0 million in 2024[46] - Current ratio improved from 1.6 to 1.8, and quick ratio improved from 1.1 to 1.4[51] - Total liabilities to total assets ratio increased from 47.1% to 62.9%[51] - The company recorded a decrease in inventory of RMB 2,298,000 for the first half of 2025, compared to a decrease of RMB 2,555,000 in the same period of 2024[88] - The total cash and cash equivalents at the end of the period increased to RMB 63,675,000 from RMB 45,458,000 at the beginning of the period, reflecting a net increase of RMB 18,451,000[88] Corporate Governance and Compliance - The company has adopted corporate governance principles and regularly reviews compliance with the corporate governance code, maintaining high standards throughout the reporting period[62] - The audit committee, consisting of one non-executive director and two independent non-executive directors, reviewed and confirmed that the interim financial results for the six months ended June 30, 2025, complied with relevant accounting standards[66] - The board of directors and management confirmed compliance with the securities trading standards throughout the reporting period[64] Shareholding Structure - As of June 30, 2025, the total issued share capital was 239,110,000 shares, with significant shareholdings by directors and senior management, including 33.64% held by Mr. Lu in non-listed shares[70] - The company has a significant concentration of ownership among major shareholders, with Li Hui and Lu Shiwen each holding over 33% of non-listed shares[73] - The total beneficial ownership of H shares by FutureX entities is 3.33%, equating to 7,963,128 shares each[79]

公司名稱: 康灃生物科技（上海）股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限 ...

Core Viewpoint - 康沣生物-B (06922) reported significant revenue growth and a reduction in losses for the first half of 2025, driven by increased sales of respiratory intervention products following regulatory approvals [1] Financial Performance - Revenue reached 51.106 million yuan, representing a year-on-year increase of approximately 162% [1] - Gross profit amounted to 34.312 million yuan, reflecting a year-on-year growth of about 125% [1] - Loss attributable to shareholders narrowed to 23.817 million yuan, a reduction of 54.35% compared to the previous year [1] - Earnings per share reported a loss of 0.1 yuan [1] Product and Market Development - Revenue growth was primarily driven by the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products by 波科国际医疗贸易 (Shanghai) Co., Ltd. also increased during the reporting period [1] Strategic Initiatives - The reduction in losses is attributed to the company's optimized development strategy and effective measures implemented for group cost control [1]

Core Viewpoint - 康沣生物-B (06922) reported a significant increase in revenue and a reduction in losses for the first half of 2025, driven by the sales of newly approved respiratory intervention products [1] Financial Performance - Revenue reached 51.106 million yuan, representing a year-on-year increase of approximately 162% [1] - Gross profit amounted to 34.312 million yuan, reflecting a year-on-year growth of about 125% [1] - Loss attributable to the parent company narrowed to 23.817 million yuan, a reduction of 54.35% compared to the previous year [1] - Earnings per share reported a loss of 0.1 yuan [1] Product and Market Development - Revenue growth was primarily driven by the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also increased during the reporting period [1] Strategic Initiatives - The reduction in losses is attributed to the company's optimized development strategy and effective measures implemented for group cost control [1]

Core Viewpoint - 康沣生物-B (06922.HK) reported significant revenue growth and reduced losses for the six months ending June 30, 2025, driven by increased sales of respiratory intervention products following regulatory approval [1] Financial Performance - Revenue increased to RMB 51.1 million, representing a year-on-year growth of 162.4% [1] - Losses decreased from RMB 56.0 million for the six months ending June 30, 2024, to RMB 27.2 million for the same period in 2025, a reduction of RMB 28.8 million or 51.4% [1] Product Development - The revenue growth was primarily attributed to the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also contributed to the revenue increase during the reporting period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 截至2025年6月30日止六個月的中期業績公告 財務摘要 截至6月30日止六個月 2025年 2024年 （未經審核） （未經審核） 人民幣千元 人民幣千元 收入 51,106 19,475 毛利 34,312 15,281 研發開支 (17,907) (37,222) 期內虧損 (27,221) (55,953) 業務摘要 於報告期間及截至本公告日期，我們在產品管線及業務營運方面取得多項進 展，包括但不限於： • 我們的收入由截至2024年6月30日止六個月的的人民幣19.5百萬元增加至截 至2025年6月30日止六個月的人民幣51.1百萬元，增加人民幣31.6百萬元， 增幅為162.4%，主要受於2025年3月獲國家藥監局批准的惡性狹窄冷凍消 融系統及冷凍粘連治療系統等呼吸介入產品的銷量增加所帶動。此外，波 科國際醫療貿易（ ...